1 / 26

Impact of Testing Strategies to Reduce Transmission Risk for HBV

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Rav i Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013. Overview of SANBS. HQ in Johannesburg. SANBS is a private not for profit company operating on a fee for service basis

reuben
Download Presentation

Impact of Testing Strategies to Reduce Transmission Risk for HBV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

  2. Overview of SANBS HQ in Johannesburg • SANBS is a private not for profit company operating on a fee for service basis • Provides a vein to vein blood transfusion service in 8 of the 9 provinces in SA. • WPBTS in Western Cape • 807,000 units of blood collected annually (100% voluntary) – 2 800 units bled daily • 2 testing centres - Johannesburg and Durban • Also test for Namibia BTS (ID-NAT as well) • 7 blood processing centres • 82 blood banks serving > 600 hospitals and clinics. • SANBS is accredited with the South African National Accreditation System (SANAS) • Specific laboratories are ISO 17025 accredited

  3. Donation Testing Strategy • Quality assured testing of each donation • EQAS and internal QC systems in place • Serology is mandatory • Anti-HIV-1,2, anti-HCV, HBsAg • Quality assured testing with sensitive serology assays leads to detection of most of the viral positive donations cost effectively • Individual Donation Nucleic Acid Testing (ID-NAT) • Implemented in October 2005 • Primarily to reduce risk of HIV window period transmission but also HBV transmission as well

  4. Rationale for ID-NAT in South Africa • HIV prevalence in blood donors 0.21% • HBV prevalence in Blood Donors is 0.1% • Implemented ID-NAT testing in October 2005 • ULTRIO® assay on the TIGRIS® platform for: • HIV-1 RNA • HCV RNA • HBV DNA • Serology testing for anti-HIV, anti-HCV and HBsAg done concurrently • Evaluated and implemented Ultrio Plus assay in May 2011 because of increased sensitivity for HBV detection in window period

  5. Geographic Distribution of Chronic HBV Infection HBsAg Prevalence ³8% - High WHO 2-7% - Intermediate <2% - Low

  6. HBV 5 Year data

  7. Hepatitis B Summary • 476 NAT+, HBsAg negative donations detected in 5 years • Hundreds of cases of transmission via transfusion prevented • ID NAT testing has had a significant positive impact on reducing risk of HBV transmission via blood transfusion • However still a risk of non detection of very low viral load donations • One confirmed HBV transmission on a donation that tested negative with routine serology and ID-NAT • Donor triggered look back as subsequent donation positive • Ultrio Plus Assay evaluated and in 2010/11

  8. Confirmed pre-ID-NAT WP transmission case • Donor triggered look back – RBC • Platelet concentrate – Patient unable to be traced • Donor details • 47 year old white male (low risk, regular donor) • 54 previous donations • Negative donation – 26/11/2008 • Date of Transfusion – 10/12/2008 • Positive donation – 26/01/2009

  9. ID-NAT WP transmission case * 3.5 months after transfusion

  10. Additional tests to Determine if Recipient infection caused by Transfusion • Donor plasma index donation (26/11/08) • SANBS 3 out of 30 replicates positive • Gen Probe 7 out of 30 replicates positive with Ultrio Plus • Phylogenetic analysis/sequencing • Donor and recipient – genotype A • Intra group nucleotide divergence • Donor/recipient 0.31% (99.7% Shared Identity) • Transmission by Blood Tranfusionconfirmed

  11. Ultrio, Ultrio Plus, TaqScreen Study performed • Compare Sensitivity of NAT assays with a range of samples • 10 000 random samples • 40 HIV ID-NAT yield samples • 107 HBV ID NAT positive samples on Ultrio • HBsAg positive, HBV NAT negative samples • Other samples (HIV Window period transmission sample and HBV window period transmission sample)

  12. Proportion reactive per NAT option on 107 Ultrio HBV ID-NAT yield samples % reactive tested in 6 replicates in each test option p< 0.00001 p< 0.00001 p< 0.00001 P= 0.00015 NAT option

  13. Proportion HBV NAT reactive on WP* and OBI yield samples % reactive NAT option

  14. Percent ID-NAT reactive on HBsAg+/Ultrio- yield samples % reactive (12 reps) copies/ml* *determined by probit analysis in Ultrio Plus against Eurohep standard

  15. HBV ID-NAT Yields – One year Data Ultrio (2010 vs. Ultrio Plus 2011)

  16. Viral load distribution in all HBV NAT yields detected by Ultrio versus Ultrio Plus HBV-DNA cps/mL

  17. Estimated WP reduction with Ultrio and Ultrio Plus (14.5 vs 24.7 days; 1.7 fold) Start WP Ultrio Plus Ultrio HBsAg cps/ml HBsAg S/CO=1 3000 cps/ml Ultrio 50% LOD 63 cps/ml Ultrio Plus 50% LOD 4.1 cps/ml ID50 3.16 cps/ 20 ml 24.7 days 12.9 days days Ultrio Plus HBsAg eclipse WP 14.5 days 22.9 days WP Ultrio

  18. Probable OBI transmission case ¥ 100 % homology of whole HBV genotype D genome sequence of donor sample 11/4/12 and recipient sample 4/7/12 (analysis kindly performed by Dr Marco Koppelman, Sanquin, Amsterdam) * Estimated from 5/20 reps Ultrio Plus reactive by probit analysis ( 5.1% probability of transmission estimated with ID50 of 316 virions)

  19. Testing Strategy for Hepatitis B • Countries with high incidence/prevalence of HBV need to carefully review algorithms for HBV testing and assay selection • Maximise safety and minimise product discard • High prevalence countries • HBsAg and ID-NAT but not anti-HBc • No discard of anti-HBc positive units (6-8% of products usable) • Majority of early and occult infections detected • Minimal risk of not detecting post HBV DNA window period donations and some OBI’s • Ultrio Plus in ID-NAT format has significantly improved sensitivity and reduced risk

  20. Course of HBV markers and residual transmission risk with ID-NAT OBI transmission risk unknown 1st WP ~10 days (Ultrio Plus) 2nd WP < 1day (Ultrio Plus) Vermeulen et al, Transfusion 2012;52:880-892.

  21. SANBS Algorithm for HBV Testing • ID-NAT and HBsAg testing • Concordant positive – confirmed • ID-NAT only (2 x U+ and dHxV) • Non repeat reactive – donation discarded, anti-HBc and anti-HBs marker added • 0.12% of donations discarded (mostly false positive) • Donor not notified • When donor returns • Additional tests performed • Blood can be used if all routine tests and anti-HBc negative

  22. Algorithm for HBV Testing (cont’d) • ID-NAT repeat reactive (2 out of 4), serology negative • Additional tests on plasma bag • Donor recalled and additional tests done • If confirmed positive defer donor • If deferral, medical division contacts and counsels donor • If all tests on follow up donation negative (review need for additional tests or re-instate)

  23. HIV infections in six years of ID-NAT screening of 4,520,230 donations anti-HIV HIV-RNA 7993 (96.5%) HIV RNA +, anti-HIV + concordant HIV RNA –, anti-HIV + elite controller 64 (0.77%) HIV RNA +, anti-HIV– window period 228 (2.8%) • 59 in first time donors (0.71%) • 4 in lapsed donors (0.05%) • 1 in repeat donor (0.01%)* 82/228 (38.4%) HIV-Ag + 136 HIV-Ag-, RNA+ infections avoided (1:33,237)

  24. Impact of ID NAT on Blood Safety - HIV • Significant positive impact on blood safety contributing to major public health success story • 136 ID- NAT positive, anti-HIV negative, p24 antigen negative donations detected in 6 years of testing. • Without ID-NAT there would have been numerous HIV transmissions via blood transfusion • Major public health success story • Increased collections by 95 000 units over 5 years and increased confidence in the blood supply • Could increase Black donors from 7% to 31% of donor base over 5 years • Since ID NAT implementation, no reported case of HIV transmission since October 2005 • HIV prevalence in blood donors has increased (0.07% to 0.23%) • Highlights impact of ID-NAT on improving blood safety

  25. Summary • Implementation of ID-NAT testing has resulted in a significant increase in safety of the South African blood supply compared to previous testing strategy • ID-NAT continues to interdict infectious donations that are missed in mini pool format • SANBS evaluation and one year data confirmed that Ultrio Plus is more sensitive than Ultrio for HBV

  26. Thank You

More Related